- Home
- FLC vs DSGN Comparison
FLC vs DSGN Comparison
Compare FLC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- DSGN
- Stock Information
- Founded
- FLC 2003
- DSGN 2017
- Country
- FLC United States
- DSGN United States
- Employees
- FLC N/A
- DSGN N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- DSGN Health Care
- Exchange
- FLC Nasdaq
- DSGN Nasdaq
- Market Cap
- FLC 174.2M
- DSGN 208.9M
- IPO Year
- FLC N/A
- DSGN 2021
- Fundamental
- Price
- FLC $17.45
- DSGN $5.82
- Analyst Decision
- FLC
- DSGN
- Analyst Count
- FLC 0
- DSGN 0
- Target Price
- FLC N/A
- DSGN N/A
- AVG Volume (30 Days)
- FLC 37.8K
- DSGN 184.3K
- Earning Date
- FLC 01-01-0001
- DSGN 11-06-2025
- Dividend Yield
- FLC 6.64%
- DSGN N/A
- EPS Growth
- FLC N/A
- DSGN N/A
- EPS
- FLC N/A
- DSGN N/A
- Revenue
- FLC N/A
- DSGN N/A
- Revenue This Year
- FLC N/A
- DSGN N/A
- Revenue Next Year
- FLC N/A
- DSGN N/A
- P/E Ratio
- FLC N/A
- DSGN N/A
- Revenue Growth
- FLC N/A
- DSGN N/A
- 52 Week Low
- FLC $12.62
- DSGN $2.60
- 52 Week High
- FLC $15.45
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- FLC 76.91
- DSGN 59.68
- Support Level
- FLC $17.15
- DSGN $4.92
- Resistance Level
- FLC $17.25
- DSGN $6.57
- Average True Range (ATR)
- FLC 0.09
- DSGN 0.46
- MACD
- FLC 0.02
- DSGN 0.05
- Stochastic Oscillator
- FLC 97.57
- DSGN 60.48
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.